• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疲劳和瘙痒是原发性胆汁性肝硬化侵袭性更强亚组的特征。

Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis.

机构信息

Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Azienda Ospedaliera Universitaria Sant'Orsola-Malpighi, Bologna, Italy.

出版信息

Liver Int. 2015 Feb;35(2):636-41. doi: 10.1111/liv.12560. Epub 2014 Apr 23.

DOI:10.1111/liv.12560
PMID:24698666
Abstract

BACKGROUND & AIMS: In recent years, primary biliary cirrhosis is mostly diagnosed in patients who are asymptomatic; however, a proportion of cases still present with typical complaints such as fatigue and/or pruritus. We compared biochemical, histological and immunological features of patients with or without fatigue and/or pruritus at onset to see whether the different clinical presentation may eventually impact on disease progression.

METHODS

We analysed the Bologna cohort of 216 patients with primary biliary cirrhosis referred to our Centre between 1997 and 2007, according to symptomatic (fatigue and/or pruritus) or asymptomatic presentation. Clinical, biochemical, histological and immunological feature at diagnosis, response to ursodeoxycholic acid and progression of the disorder were compared after a mean follow-up of 81 ± 75 months.

RESULTS

At diagnosis, symptomatic patients were significantly more often women (98.6% vs. 87.2%, P = 0.004), younger (mean age 49 ± 12 vs. 55 ± 12 years, P = 0.003) and with more pronounced biochemical activity, as indicated by higher alkaline phosphatase (mean 2.93 ± 2 vs. 2.12, P = 0.002) and aminotransferase (mean 1.92 ± 1 vs. 1.47 ± 1.27, P = 0.014) levels, whereas histological stage and autoantibody profile were similar. Symptomatic patients were less likely to respond to ursodeoxycholic acid therapy (63% vs. 81%, P = 0.006) and developed more often cirrhosis and its complications (31% vs. 13%, P = 0.004).

CONCLUSIONS

Fatigue and/or pruritus at onset identify a subset of patients with primary biliary cirrhosis who preferentially are women, younger, with a particularly active disease, less responsive to ursodeoxycholic acid treatment, and more inclined to evolve to cirrhosis and its complications.

摘要

背景与目的

近年来,原发性胆汁性肝硬化多在无症状患者中诊断;然而,仍有一部分病例表现为典型的疲劳和/或瘙痒症状。我们比较了有或无疲劳和/或瘙痒症状的患者的生化、组织学和免疫学特征,以了解不同的临床表现是否最终会影响疾病的进展。

方法

我们根据症状(疲劳和/或瘙痒)或无症状表现,分析了 1997 年至 2007 年间我们中心收治的 216 例原发性胆汁性肝硬化患者的博洛尼亚队列。在平均随访 81±75 个月后,比较了诊断时的临床、生化、组织学和免疫学特征、对熊去氧胆酸的反应以及疾病的进展情况。

结果

在诊断时,有症状的患者中女性(98.6% vs. 87.2%,P=0.004)、年龄较小(平均年龄 49±12 岁 vs. 55±12 岁,P=0.003)和生化活性较高的患者明显更多,表现为碱性磷酸酶(平均 2.93±2 vs. 2.12,P=0.002)和氨基转移酶(平均 1.92±1 vs. 1.47±1.27,P=0.014)水平较高,而组织学分期和自身抗体谱相似。有症状的患者对熊去氧胆酸治疗的反应性较低(63% vs. 81%,P=0.006),更容易发展为肝硬化及其并发症(31% vs. 13%,P=0.004)。

结论

发病时的疲劳和/或瘙痒可识别出原发性胆汁性肝硬化患者的一个亚组,这些患者更倾向于是女性、年轻、疾病活动度特别高、对熊去氧胆酸治疗反应较差、更倾向于发展为肝硬化及其并发症。

相似文献

1
Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis.疲劳和瘙痒是原发性胆汁性肝硬化侵袭性更强亚组的特征。
Liver Int. 2015 Feb;35(2):636-41. doi: 10.1111/liv.12560. Epub 2014 Apr 23.
2
Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.甲氨蝶呤用于对熊去氧胆酸治疗生化反应不完全的原发性胆汁性肝硬化患者进行症状性治疗。
Aliment Pharmacol Ther. 2006 Sep 1;24(5):813-20. doi: 10.1111/j.1365-2036.2006.03048.x.
3
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.熊去氧胆酸长期治疗原发性胆汁性肝硬化:长达12年的随访
Aliment Pharmacol Ther. 2005 Feb 1;21(3):217-26. doi: 10.1111/j.1365-2036.2005.02318.x.
4
Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.原发性胆汁性肝硬化及原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征的临床、生化特征及治疗反应
Hepatogastroenterology. 2002 Sep-Oct;49(47):1195-200.
5
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.熊去氧胆酸治疗原发性胆汁性肝硬化的加拿大多中心双盲随机对照试验
Hepatology. 1994 May;19(5):1149-56.
6
Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.原发性胆汁性肝硬化患者长期服用熊去氧胆酸后胆汁酶水平及瘙痒症状的改善
Am J Gastroenterol. 1990 Jan;85(1):15-23.
7
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.利妥昔单抗治疗对熊去氧胆酸应答不佳的原发性胆汁性肝硬化患者的 B 细胞耗竭。
Am J Gastroenterol. 2013 Jun;108(6):933-41. doi: 10.1038/ajg.2013.51. Epub 2013 May 7.
8
Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis.抗线粒体抗体阴性的原发性胆汁性肝硬化:原发性胆汁性肝硬化的一个亚组
Liver Int. 2008 Feb;28(2):233-9. doi: 10.1111/j.1478-3231.2007.01651.x.
9
Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.原发性胆汁性肝硬化(I期)对熊去氧胆酸治疗的长期反应。
Hepatogastroenterology. 2005 May-Jun;52(63):753-6.
10
Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy.熊去氧胆酸治疗原发性胆汁性肝硬化的进展
Gastroenterology. 1992 Apr;102(4 Pt 1):1389-91.

引用本文的文献

1
Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis.过氧化物酶体增殖物激活受体激动剂在原发性胆汁性胆管炎中的疗效与安全性:一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2025 Sep 3;18:17562848251370111. doi: 10.1177/17562848251370111. eCollection 2025.
2
Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis.肿瘤坏死因子α诱导蛋白3:原发性胆汁性胆管炎中对熊去氧胆酸反应的关键生物标志物。
World J Hepatol. 2025 Jul 27;17(7):107666. doi: 10.4254/wjh.v17.i7.107666.
3
Risk assessment of heavy metal toxicity induced by platinum accumulation in tumor patients.
肿瘤患者铂蓄积所致重金属毒性的风险评估
PeerJ. 2025 May 12;13:e19375. doi: 10.7717/peerj.19375. eCollection 2025.
4
Serum Autotaxin Levels Predict Liver-Related Events in Patients With Primary Biliary Cholangitis: A Long-Term Multicenter Observational Study.血清自分泌运动因子水平可预测原发性胆汁性胆管炎患者的肝脏相关事件:一项长期多中心观察性研究。
Clin Transl Gastroenterol. 2024 Dec 1;15(12):e00779. doi: 10.14309/ctg.0000000000000779.
5
Understanding fatigue and pruritus in primary biliary cholangitis.原发性胆汁性胆管炎中的疲劳与瘙痒
Clin Liver Dis (Hoboken). 2024 May 31;23(1):e0216. doi: 10.1097/CLD.0000000000000216. eCollection 2024 Jan-Jun.
6
Evolutionary relationship between antimitochondrial antibody positivity and primary biliary cholangitis in Taiwan: a 16-year hospital cohort study.台湾地区抗线粒体抗体阳性与原发性胆汁性胆管炎之间的进化关系:一项为期16年的医院队列研究。
Therap Adv Gastroenterol. 2024 Mar 28;17:17562848241241227. doi: 10.1177/17562848241241227. eCollection 2024.
7
Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center.评估转诊至中东肝病中心(MELD)的自身免疫性肝病患者的自然病史。
BMC Gastroenterol. 2024 Jan 4;24(1):17. doi: 10.1186/s12876-023-03105-7.
8
High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.高中性粒细胞与淋巴细胞比值预示原发性胆汁性胆管炎患者对熊去氧胆酸的应答更差:一项回顾性队列研究。
BMC Gastroenterol. 2023 Nov 17;23(1):400. doi: 10.1186/s12876-023-03031-8.
9
ChIP-seq analysis found IL21R, a target gene of GTF2I-the susceptibility gene for primary biliary cholangitis in Chinese Han.ChIP-seq 分析发现,IL21R 是 GTF2I 的靶基因——中国汉族原发性胆汁性胆管炎的易感基因。
Hepatol Int. 2024 Apr;18(2):509-516. doi: 10.1007/s12072-023-10586-x. Epub 2023 Sep 15.
10
Risk Stratification in Primary Biliary Cholangitis.原发性胆汁性胆管炎的风险分层
J Clin Med. 2023 Sep 1;12(17):5713. doi: 10.3390/jcm12175713.